MARKET

ALEC

ALEC

Alector
NASDAQ
6.12
+0.04
+0.66%
Opening 09:31 03/28 EDT
OPEN
6.08
PREV CLOSE
6.08
HIGH
6.12
LOW
6.08
VOLUME
3.35K
TURNOVER
0
52 WEEK HIGH
9.07
52 WEEK LOW
3.660
MARKET CAP
585.99M
P/E (TTM)
-3.9301
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ALEC last week (0318-0322)?
Weekly Report · 3d ago
Alector: Initial statement of beneficial ownership of securities
Press release · 03/21 22:23
Alector Inc Announces Board Retirement and New Members
TipRanks · 03/21 20:12
Weekly Report: what happened at ALEC last week (0311-0315)?
Weekly Report · 03/18 09:17
Weekly Report: what happened at ALEC last week (0304-0308)?
Weekly Report · 03/11 09:17
Have Insiders Sold Alector Shares Recently?
Co-Founder of Alector, Inc. (NASDAQ:ALEC) recently sold US$130k worth of stock at US$6.92 per share. The sale of shares by Arnon Rosenthal amounts to 0.4% of the company's share price. A lector insiders didn't buy any shares over the last year. The company has a 9.5% of shares in the company, but there's been no insider buying in the last three months. It's worth analysing the nature of insider transactions at Alectors.
Simply Wall St · 03/08 10:29
Alector’s Clinical Progress and Financial Health Anchor Buy Recommendation
TipRanks · 03/07 05:06
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
NKGen Biotech stock is rocketing more than 65% alongside heavy pre-market trading. Infobird shares are soaring close to 53% with strong early morning trading. Earnings reports, share offerings and more are the biggest pre- market stock movers this morning.
Investorplace · 03/06 12:23
More
About ALEC
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration diseases. The Company is engaged in developing therapies designed to counteract these pathologies simultaneously by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. Its product candidates: latozinemab (AL001), AL002, and AL101, are in clinical development. Its immune-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients.

Webull offers Alector Inc stock information, including NASDAQ: ALEC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALEC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALEC stock methods without spending real money on the virtual paper trading platform.